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Little information is available on the immune response to
parvovirus B19 after the administration of contaminated
blood products. In the present study, we found that levels
of B19 IgG in B19-seropositive recipients protect against re-
infection and, after transfusion with pooled plasma contain-
ing B19 DNA ( IU/mL), increase from 19–39 IU/mL81.6 10
to 50–100 IU/mL. We found that, in the presence of 1.6–2.2
108 IU of B19 DNA/mL in B19-seronegative recipients, a
pooled-plasma B19 IgG level of 59.5 IU/mL is insufficient to
prevent B19 transmission and subsequent seroconversion.
These data should lead to improvements in the assessment
of blood-product safety.
Parvovirus B19 can cause severe disease in immunocompro-
mised individuals, and B19 infection during pregnancy can lead
to fetal mortality. B19 infection is transmitted either via re-
spiratory secretions or via administration of contaminated
blood or blood products. The latter mode of transmission is
especially problematic because of the high resilience of B19 to
many of the treatments used in plasma processing, such as
solvent-detergent treatment, lyophilization, and high temper-
atures [1], and also because of the extremely high levels of
viremia in acutely infected, and often asymptomatic, individuals
(11012 B19 DNA genome equivalents [GE]/mL or IU/mL) [2].
Significant efforts to minimize the B19 viral load in blood
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products commenced in the late 1990s because of the advent
of robust DNA extraction and B19 polymerase chain reaction
methodologies in addition to cases of B19 seroconversion in
healthy volunteers who received contaminated plasma as part
of a postmarketing surveillance study [3]. Most manufacturers
now undertake minipool B19 nucleic acid testing to reduce
plasma-pool levels of B19 DNA to !104 IU/mL, to conform
with US Food and Drug Administration (FDA) proposals
(available at: http://www.fda.gov/). Standardization of B19
DNA and IgG quantitation, as well as the establishment of
validated serological assay systems, has also contributed to im-
provements in blood-product screening paradigms. The reg-
ulatory requirement that levels of B19 DNA in anti-D antibody
preparations be !104 IU/mL [4] further illustrates the actions
taken by regulatory agencies to effectively improve blood-prod-
uct safety.
In the future, because of enhanced screening protocols, B19
transmission after the administration of blood products should
become a less frequent event. However, heightened awareness
of B19 has resulted in the emergence of relevant information
regarding the infectious dose of B19 and the role played by
B19 IgG in attenuating transmission. Koenigbauer et al. [5]
reported a case of B19 infection in a 36-year-old woman that
resulted from administration of a solvent/detergent-treated
pooled plasma that was subsequently recalled by the American
Red Cross after high levels (107–108 GE/mL B19 DNA) of B19
DNA were detected by the manufacturer. Blumel et al. [6] de-
tailed 2 cases of B19 infection resulting from the administration
of B19 IgG plasma protein–complex concentrates: 1 individual
received 180 mL of heat-treated concentrate containing 8.6
106 GE of B19 DNA/mL ( GE total), and the other91.5 10
received 996 mL of material containing GE of B1934 10
DNA/mL (3.9106 GE total). The transmission of B19 by a
factor VIII concentrate (free of B19 IgG) has been documented
in a case in which seroconversion occurred as a result of in-
fusion of IU of B19 DNA ( IU/mL) [7]. Sol-4 32 10 1.3 10
vent/detergent-treated plasma (Plas+SD) has also been iden-
tified, subsequent to a postmarketing surveillance study of this
product, as the source of B19 infection that occurred in 18
individuals [3, 8]. It was concluded that B19 IgG in pooled
plasma ( IU of B19 IgG/mL; [9]) was not protective64.7 17.5
in the presence of high B19 viral titers (107–108 GE/mL) and
that plasma lots containing low viral titers (100.5–103.5 GE/mL)
did not cause B19 infection in plasma recipients. However, de-
tailed serological analysis of this event has not been forthcom-
ing, and the significance that the data have for wider issues of
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Table 1. Classification of pooled-plasma recipi-
ents, according to B19 IgG reactivity against con-
formational epitopes on B19 VP2.
Group no.,
pooled-plasma–
recipient code no.
Plasma pool
transfused B19 DNA level
Group I
01002 PS3 1.6  108 IU/mL
01052 NA NA
01098 PS3 1.6  108 IU/mL
Group II
01023 PS2A 103.5 GE/mL
01053 PS2A 103.5 GE/mL
01055 NA NA
Group III
01005 PS1 2.2  108 IU/mL
01048 PS1 2.2  108 IU/mL
01057 PS1 2.2  108 IU/mL
01069 PS3 1.6  108 IU/mL
NOTE. Plasma pools PS1 and PS3 contained 59.5 and 72.0
IU of B19 IgG/mL, respectively [9]. The level of B19 DNA in
plasma pool PS2A was provided by A. Lazo. Group I and II
recipients remained symptom free, whereas group III recipi-
ents experienced mild fever and malaise, after transfusion.
Group I, recipients who were seropositive before transfusion
( ); group II, recipients who were seronegative bothbeforenp 3
and after transfusion ( ); group III, recipients who werenp 3
seronegative before transfusion and seropositive after trans-
fusion ( ); GE, genome equivalent; NA, not available.np 4
B19 infectivity and immunity merits consideration. In the pres-
ent article, we describe the serological analysis of specimens
obtained from 10 individuals who participated in the post-
marketing study [3, 8]; this analysis extends our knowledge of
the immune response to B19 exposure.
Materials and methods. As part of a postmarketing study,
100 adult volunteers, previously determined to be B19 IgG+ by
use of an Escherichia coli–based EIA to detect B19 IgG, were each
transfused with 1 unit (200 mL) of pooled plasma (Plas+SD)
[3, 8, 10]. Paired plasma specimens (blinded) were obtained
pretransfusion and 1 month posttransfusion from 10 of the
volunteers.
The 20 plasma specimens were analyzed for both B19 IgM
and B19 IgG reactivity against capsid (conformational) VP2
(VP2-N), by use of FDA-approved EIAs (Biotrin). B19 IgG
levels were quantified using the World Health Organization B19
IgG International Standard (93/724) [11]. Furthermore, B19
IgG reactivity against conformational (N) and linear (D) epi-
topes on VP1 (VP1-N and VP1-D, respectively) and to linear
VP2 (VP2-D) was analyzed as described elsewhere [12]. The
subsequent classification of pooled-plasma recipients into groups
I, II, and III, as well as the details of plasma pools used for
transfusion, is shown in table 1.
Results. Figure 1A shows that specimens from groups I and
II contained no VP2-specific IgM reactivity, whereas specimens
from group III exhibited high levels of B19 IgM reactivity post-
transfusion, thereby confirming acute B19 infection in this co-
hort. Analysis of the B19 IgG reactivity of individual plasma
specimens was performed both pre- and posttransfusion, and
3 specimens (01002, 01052, and 01098) of 10 exhibited reac-
tivity against VP2-N pretransfusion, with the range of B19 IgG
in these specimens being 19–39 IU/mL (figure 1B, group I);
there was a subsequent increase in the level of B19 IgG reactivity
posttransfusion, which resulted in 2 of 3 specimens (both trans-
fused with plasma pool PS3 [table 1]) exhibiting B19 IgG levels
1100 IU/mL and the third specimen exhibiting an increase to
50 IU/mL.
A further 3 specimens (01023, 01053, and 01055), 2 of which
were from individuals transfused with plasma pool PS2A (table
1), were seronegative for antibodies against VP2-N (B19 IgG
!3 IU/mL), both pre- and posttransfusion (figure 1B, group II).
The remaining 4 paired pretransfusion specimens tested con-
tained no detectable B19 IgG against VP2-N; however, the cor-
responding paired posttransfusion specimens exhibited evidence
of B19 seroconversion and exhibited high levels of reactivity
against VP2-N epitopes (figure 1B, group III); this reactivity
corresponded to B19 IgG levels 1100 IU/mL in 2 of 4 of the
specimens, whereas the remaining 2 specimens contained lower
levels of B19 IgG, equivalent to 50 and 78 IU/mL, respectively.
For each specimen, the pattern of reactivity against VP1-N epi-
topes was identical to that exhibited against VP2-N, whereby
IgG specific for VP1-N was increased posttransfusion in group
I and was also evident only posttransfusion in group III (figure
1C).
When specimens were analyzed for reactivity against VP1-
D epitopes, 2 specimens (01002 and 01098) of 3 from group
I did not exhibit significant pretransfusion IgG reactivity; how-
ever, these 2 specimens did display significant posttransfusion
antibody reactivity (mean  SD IgG index value, 3.5 1.7
[IgG index value 11.1 is reactive]) (figure 1D). The remaining
specimen (01052) was seronegative for VP1-D IgG, both pre-
and posttransfusion. Group II specimens were unreactive against
VP1-D. All group III specimens were seronegative for B19 VP1-
D IgG pretransfusion; posttransfusion, however, all had high
levels of antibody reactivity against VP1-D epitopes (mean 
SD IgG index value, ).3.9 0.96
B19 IgG reactivity was observed only against VP2-D epitopes
in group III specimens, with a mean  SD VP2-D IgG index
value of (figure 1E). It should be noted that, although4.5 1.8
posttransfusion group I specimens exhibited an increase in lev-
els of B19 IgG against VP2-N epitopes (figure 1B), they had
no increase in antibody reactivity to VP2-D epitopes.
Discussion. The present study demonstrates that, in B19-
seropositive recipients transfused with plasma containing high
levels of B19 DNA ( IU/mL), levels of parvovirus B1981.6 10
IgG against VP1-N and VP2-N epitopes and against linear
Figure 1. A, B19 IgM reactivity against conformational VP2, in pooled-plasma recipients (before and after transfusion). Reactivity is measured as IgM index value (reactivity 11.1 is reactive [dashed
line] ). B, B19 IgG reactivity against capsid (conformational) VP2 (VP2-N), as determined by EIA and expressed as IU/mL, in pooled-plasma recipients. C, B19 IgG reactivity against conformational epitopes
on VP1 (VP1-N), in pooled-plasma recipients. Reactivity is assessed using an immunofluorescence assay and is graded, according to the manufacturer’s instructions on a scale of 1–4, depending on the
extent of fluorescence. D, B19 IgG reactivity against linear VP1 (VP1-D), in pooled-plasma recipients (before and after transfusion). E, B19 IgG reactivity against linear VP2 (VP2-D), in pooled-plasma
recipients. D and E, Reactivity measured as IgG index value (index value is specimen:cutoff OD ratio; reactivity 11.1 is reactive [dashed line] ).
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epitopes on the unique region of VP1 increase dramatically.
Moreover, it also proposes that the levels of B19 IgG in
pooled-plasma products protect against infection in B19-se-
ronegative recipients when only low levels of B19 DNA (i.e.,
!103.5 GE/mL) are present. Finally, we have shown that, in the
presence of IU of B19 DNA/mL, B19 IgG lev-81.6–2.2 10
els of 59.5 (plasma pool PS1) and 72.0 IU/mL (plasma pool
PS3), respectively, are insufficient to prevent B19 transmission
to B19-seronegative recipients (group III) and subsequent
seroconversion.
Group I recipients were seropositive for B19 IgG before
transfusion with pooled plasma. The level of IgG specific for
VP2-N increased to 1100 IU/mL in 2 recipients after trans-
fusion with plasma pool PS3; however, the observed increase
in the remaining recipient (01052) was lower (50 IU/mL). This
subsequent increase in IgG response was mirrored by the in-
creased reactivity against VP1-N that was observed posttrans-
fusion, whereby the increase in fluorescence exhibited by the
specimen from recipient 01052 was less than that for the others
in group I. It is relevant that, because of the presence of high-
titer B19 DNA, blood products lacking B19-specific antibodies
were most at risk of transmitting B19 infection and that, despite
high levels of B19 DNA, recipients with preexisting B19 IgG
(or who were the administered blood products containing B19
IgG) were not infected [13]. Plentz et al. [14] have also con-
firmed that the presence of B19 IgG in either the recipients of
the blood products or in the administered material offers pro-
tection against B19 DNA (at concentrations of !6102–2.2
106 GE/mL) present in therapeutic products, to the extent
that no individual ( ) receiving a B19-contaminated bloodnp 14
product showed symptoms of acute B19 infection. The results
of the present study demonstrate that, in a healthy immuno-
competent individual (recipient 01098), a B19 IgG level of 19
IU/mL confers protection against the development of symp-
toms of B19 infection when that individual is reexposed to the
virus. To our knowledge, the present study is the first to dem-
onstrate that there is a specific level of B19 IgG that protects
against reinfection. The postexposure B19 IgG profile will also
contribute to avoidance of reinfection.
Although all recipients in group I had either lost or never
developed antibody reactivity against VP1 or VP2 epitopes be-
fore transfusion, 2 of them subsequently displayed strong IgG
responses against linear epitopes on the VP1-unique region only
and not against VP2-D. This observation is in accordance with
the work of Soderlund et al. [15] and significantly strengthens
our hypothesis that VP1-specific B-cell memory is maintained
only with respect to linear epitopes of the unique region of
VP1, as well as with respect to VP1-N/VP2-N epitopes [12].
Recipient 01052 in group 1 exhibited the lowest increase in
B19 IgG reactivity after transfusion and was seronegative for
antibody reactivity against VP1-D both before and after trans-
fusion, possibly as a result of infusion with plasma containing
a B19 viral load lower than that required for reactivation of
the memory response.
Group II recipients all remained seronegative after receipt of
pooled plasma. Although information was not available on which
plasma pool was transfused into recipient 01055, both recipient
01023 and recipient 01053 were transfused with plasma pool
PS2A, which contained 103.5 B19 GE/mL [3]. Given that the mean
level of B19 IgG observed in pooled plasma is IU/64.7 17.5
mL [9], it is clear that B19 IgG within this range appears to be
protective against infection of seronegative recipients when the
B19 viral load is 103.5 B19 GE/mL.
Group III recipients who underwent B19 seroconversion af-
ter transfusion exhibited both strong VP2-specific IgM reac-
tivity and significant levels of B19 IgG against VP2-D epitopes.
The latter result is in accordance with previously published
findings that production of antibody directed against VP2-D
epitopes occurs shortly after exposure to B19 [15].
Traditionally, plasma-product manufacturers have relied on
the presence of high levels of B19 IgG in pooled-plasma prod-
ucts alone to indicate product safety [2]. The data presented
in the present study reinforce the strategy of identifying and
removing high-titer B19 plasma donations from plasma pools,
given that 4 of 7 recipients seroconverted because of the pres-
ence of B19 DNA in solvent/detergent-treated pooled human
plasma. Although many companies have introduced minipool
screening to address this problem, such screening is not pres-
ently mandatory, despite the fact that it is usually high-risk
populations (e.g., pregnant women and immunocompromised
patients) who are administered such products. This regulatory
ambiguity is likely to change in coming years, as improved
product-safety profiles are demanded by consumers.
In summary, the present study has provided new data rel-
evant to the B19 IgG level necessary to confer protection after
reexposure to the virus, as well as to the B19 IgG level that, in
pooled-plasma products, may prevent infection of seronegative
recipients.
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